The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.
about
New molecularly targeted therapies for lung cancerSpatial regulation of epidermal growth factor receptor signaling by endocytosisRegulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in CancerEGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptorPolymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancersDisplayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines.Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cellsA bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancerTAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status.Photochemical internalization of tumor-targeted protein toxins.Prognostic biomarkers in ovarian cancer.Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.The landscape of alternative splicing in cervical squamous cell carcinoma.Epidermal growth factor receptor expression in canine transitional cell carcinomaEvaluation of apoptogenic adenovirus type 5 oncolytic vectors in a Syrian hamster head and neck cancer modelUrothelial carcinomas: a focus on human epidermal receptors signalingHER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cellsRole of β4 integrin phosphorylation in human invasive squamous cell carcinoma: regulation of hemidesmosome stability modulates cell migrationEndosomal accumulation of the activated epidermal growth factor receptor (EGFR) induces apoptosisDefective downregulation of receptor tyrosine kinases in cancerIntegrated analysis reveals that STAT3 is central to the crosstalk between HER/ErbB receptor signaling pathways in human mammary epithelial cells.Genetic and biochemical alterations in non-small cell lung cancer.Braf and erbB2 mutations correlate with smoking status in lung cancer patients.Ubiquitylation and cell signalingYes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.Molecular biology of epidermal growth factor receptor inhibition for cancer therapy.Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendationsRNA interference screen identifies Usp18 as a regulator of epidermal growth factor receptor synthesis.Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives.-216G/T (rs712829), a functional variant of the EGFR promoter, is associated with the pleural metastasis of lung adenocarcinoma.Ubiquitin specific protease 18 (Usp18) is a WT1 transcriptional targetNovel human antibody therapeutics: the age of the Umabs.Pathogenesis of lung cancer signalling pathways: roadmap for therapies.Down-regulation of multiple cell survival proteins in head and neck cancer cells by an apoptogenic mutant of adenovirus type 5.A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer
P2860
Q24680988-A756CAAA-C5EA-444D-BF70-34D9BE8D8F3CQ26829168-CA024E90-E3B0-4EAB-A067-3B2B6561002DQ27001635-990E56C3-932F-4C7D-B993-C0BF706C4AFFQ28538710-0B6376F7-C1B1-408B-9009-559261118505Q28728031-BCDA16CD-A5A8-4A0B-BCEC-B8F08B8E93B7Q28757672-EC72BF0C-98CC-42E6-A11A-418AEB052706Q33358967-066FB7E2-DABC-41DD-8553-23E702D29C4CQ33411775-1245A45B-4D61-4F6C-9B84-F5D4F7A5A7F8Q33514127-9B603C1C-E27F-4A54-B9DC-D3EDF97D3D95Q33689021-F9E07B79-940E-4356-BD8C-7168AF2BFEF0Q33737099-5CA82261-4607-4B16-88C4-D1AC4A289E7FQ34068201-800EC78D-60E2-45CD-8F3A-4E49C7A61525Q34086636-F38757B2-5C8A-4D18-A8C2-A778E5F7E1FBQ34685905-1B28C126-8064-4333-9EE0-D14B6DB7E609Q34783624-CD69F6E9-AA7D-4B31-94C2-4F5CB0807831Q35147084-D6195DBF-E67B-4D10-A46B-7BD986A215A5Q35158716-A9D1200C-55B4-42A8-9590-C61CEF918742Q35172558-0CF9E9AC-7263-4E64-AA37-D2BF4C492538Q35201923-84A26FCD-5820-40F0-93DD-A55AC0E3E0FAQ35249284-D114061A-35CD-4919-9D9A-649BEDF608E4Q35643854-6042FF55-A409-46A4-A2DB-68C80135E10EQ35824123-8A5745C1-1829-4A18-A6F3-6E9AE3169AA9Q35966355-71EF0EDD-3D1E-4368-9C01-690CE94E4A40Q36184584-266FE98D-DC18-4329-871C-384196E83A5FQ36224108-09F627C5-FBC4-4CDB-A193-96CBD86A01EFQ36251951-A5843432-7B6C-4186-BDB4-C4A70BB9BF88Q36269777-6E3B3690-85C4-404E-8307-47CF534A1E90Q36481002-149DA409-0C86-4181-91C0-3A403888FC0EQ37001330-C412937F-18F0-4007-8728-D6BF0170B479Q37102073-4EDD9382-D8B0-40CF-8074-9622D3C37D17Q37127313-8A9351B6-E879-4973-96FF-5F3026378D8EQ37130501-59959EBC-4DD1-4422-8112-DDF0A593707FQ37211807-2F8C61BF-8D07-409B-8656-9336A55D5E77Q37217819-44AE2C9D-0A13-4FA7-8653-8F59A39F2D18Q37243228-5848C1EF-30D4-4487-8363-F877102CD527Q37389526-D63960C0-A0D4-4DC3-8F9C-5DF84AFEC063Q37414129-4FB5B448-21A3-4D31-8E5F-776363473EA0Q37481363-E60B79C7-DD6F-4A47-A719-6B9E09573551Q37485865-DDED920E-BD58-40DA-AE07-D95CF3F3A354Q37670436-0CA1B59F-4F08-43C7-8438-BA6F26996FB7
P2860
The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The erbB family: targets for t ...... nd tyrosine kinase inhibitors.
@ast
The erbB family: targets for t ...... nd tyrosine kinase inhibitors.
@en
type
label
The erbB family: targets for t ...... nd tyrosine kinase inhibitors.
@ast
The erbB family: targets for t ...... nd tyrosine kinase inhibitors.
@en
prefLabel
The erbB family: targets for t ...... nd tyrosine kinase inhibitors.
@ast
The erbB family: targets for t ...... nd tyrosine kinase inhibitors.
@en
P1476
The erbB family: targets for t ...... nd tyrosine kinase inhibitors.
@en
P2093
Eric K Rowinsky
P304
P356
10.1146/ANNUREV.MED.55.091902.104433
P577
2004-01-01T00:00:00Z